This prognostic impact also suggests that more specific targeting of this particular AML cell subset should be tried in AML therapy; CK2 inhibition may then be a possible strategy because CK2 inhibition has antiproliferative and pro-apoptotic effects in CD34+CD38− AML cells [56,61]. The gene discussed is CD38; the disease is acute myeloid leukemia.